PMV Pharmaceuticals Inc
For the period ended Dec 31, 2024. Filed Mar 3, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 3, 2025
PMVP$1.22-2.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 15. Exhibits, Financial Statement Schedules
EXHIBIT INDEX
| ExhibitNumber | Description | Form | File No. | Number | Filing Date |
|---|---|---|---|---|---|
| 3.1 | Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect. | 8-K | 001-39539 | 3.1 | September 29, 2020 |
| 3.2 | Amended and Restated Bylaws of the Registrant, as currently in effect. | 10-Q | 001-39539 | 3.3 | May 10, 2023 |
| 4.1 | Description of Securities of the Registrant. | 10-K | 001-39539 | 4.1 | March 3, 2021 |
| 4.2 | Specimen common stock certificate of the Registrant. | S-1/A | 333-248627 | 4.2 | September 21, 2020 |
| 4.3 | Form of Indenture. | S-3 | 333-283349 | 4.5 | November 20, 2024 |
| 10.1+ | Form of Indemnification Agreement between the Registrant and each of its directors and executive officers. | S-1 | 333-248627 | 10.1 | September 4, 2020 |
| 10.2+ | 2013 Equity Incentive Plan, as amended, and forms of agreement thereunder. | S-1/A | 333-248627 | 10.2 | September 21, 2020 |
| 10.3+ | 2020 Equity Incentive Plan and forms of agreements thereunder. | S-1/A | 333-248627 | 10.3 | September 21, 2020 |
| 10.4+ | 2020 Employee Stock Purchase Plan and forms of agreements thereunder. | 10-Q | 001-39539 | 10.4 | May 9, 2024 |
| 10.5+ | Employment Offer Letter, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D. | S-1 | 333-248627 | 10.5 | September 4, 2020 |
| 10.6+ | Employment Offer Letter, dated February 22, 2021, by and between the Registrant and Deepika Jalota, Pharm.D. | 10-K | 001-39539 | 10.8 | March 1, 2022 |
| 10.7+ | Employee Incentive Compensation Plan. | S-1 | 333-248627 | 10.9 | September 4, 2020 |
| 10.8+ | Change in Control and Severance Policy. | S-1 | 333-248627 | 10.10 | September 4, 2020 |
| 10.9+ | Amended and Restated Change in Control and Severance Policy Participation Agreement, dated August 17, 2020, by and between the Registrant and David H. Mack, Ph.D. | S-1 | 333-248627 | 10.11 | September 4, 2020 |
| 10.10+ | Amended and Restated Change in Control and Severance Policy Participation Agreement, dated March 23, 2022, by and between the Registrant and Deepika Jalota, Pharm.D. | 10-Q | 001-39539 | 10.14 | May 10, 2022 |
| 10.11+ | Amended Outside Director Compensation Policy. | 10-K | 001-39539 | 10.15 | February 29, 2024 |
| 10.12+ | Consulting Agreement, dated January 1, 2016, by and between the Registrant and Arnold Levine, Ph.D. | S-1 | 333-248627 | 10.16 | September 4, 2020 |
| 10.13+ | Consulting Agreement, dated May 21, 2021, by and between the Registrant and Richard Heyman, Ph.D., as amended on July 16, 2021. | 10-K | 001-39539 | 10.17 | March 1, 2022 |
| 10.14 | Lease Termination Agreement, dated August 5, 2024, by and between BMR-One Research Way LLC and PMV Pharmaceuticals, Inc. | 8-K | 001-39539 | 10.1 | August 8, 2024 |
| 10.15 | Open Market Sale Agreement, dated as of October 4, 2021, between the Registrant and Jefferies LLC. | S-3ASR | 333-260012 | 1.2 | October 4, 2021 |
| 10.16+ | Amended and Restated Employment Letter, dated January 5, 2024, by and between the Registrant and Michael Carulli. | 10-K | 001-39539 | 10.22 | February 29, 2024 |
| 10.17+ | Consulting Agreement, dated February 13, 2024, by and between the Registrant and Charles Baum, MD., Ph.D. | 10-K | 001-39539 | 10.23 | February 29, 2024 |
| 10.18+ | Amended and Restated Change in Control and Severance Policy Participation Agreement, dated January 5, 2024, by and between the Registrant and Michael Carulli. | 10-K | 001-39539 | 10.24 | February 29, 2024 |
| 19.1* | Insider Trading Policy. | ||||
| 21.1 | List of Subsidiaries. | 10-K | 001-39539 | 21.1 | March 1, 2022 |
| 23.1* | Consent of Independent Registered Public Accounting Firm. | ||||
| 24.1* | Power of Attorney (contained in the signature page to this Annual Report on Form 10-K). | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*# | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2*# | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97.1+ | Compensation Recovery Policy. | 10-K | 001-39539 | 97.1 | February 29, 2024 |
| 101.INS | Inline XBRL Instance Document-the Instance Document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. |
| 101.SCH | Inline XBRL Taxonomy Extension Schema Document |
| 104 | Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101) |
- Filed herewith.
+Indicated management contract or compensatory plan.
The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of the Registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.